1. Home
  2. AGIO vs AFYA Comparison

AGIO vs AFYA Comparison

Compare AGIO & AFYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AGIO
  • AFYA
  • Stock Information
  • Founded
  • AGIO 2007
  • AFYA 1999
  • Country
  • AGIO United States
  • AFYA Brazil
  • Employees
  • AGIO N/A
  • AFYA N/A
  • Industry
  • AGIO Biotechnology: Pharmaceutical Preparations
  • AFYA Other Consumer Services
  • Sector
  • AGIO Health Care
  • AFYA Real Estate
  • Exchange
  • AGIO Nasdaq
  • AFYA Nasdaq
  • Market Cap
  • AGIO 1.4B
  • AFYA 1.6B
  • IPO Year
  • AGIO 2013
  • AFYA 2019
  • Fundamental
  • Price
  • AGIO $32.09
  • AFYA $18.23
  • Analyst Decision
  • AGIO Buy
  • AFYA Sell
  • Analyst Count
  • AGIO 8
  • AFYA 5
  • Target Price
  • AGIO $56.00
  • AFYA $17.60
  • AVG Volume (30 Days)
  • AGIO 550.4K
  • AFYA 150.7K
  • Earning Date
  • AGIO 05-01-2025
  • AFYA 05-08-2025
  • Dividend Yield
  • AGIO N/A
  • AFYA 1.27%
  • EPS Growth
  • AGIO N/A
  • AFYA 41.32
  • EPS
  • AGIO 11.45
  • AFYA 1.31
  • Revenue
  • AGIO $37,035,000.00
  • AFYA $599,363,389.00
  • Revenue This Year
  • AGIO $27.43
  • AFYA $15.09
  • Revenue Next Year
  • AGIO $189.81
  • AFYA $9.07
  • P/E Ratio
  • AGIO $2.80
  • AFYA $13.92
  • Revenue Growth
  • AGIO 25.96
  • AFYA 15.70
  • 52 Week Low
  • AGIO $23.42
  • AFYA $14.52
  • 52 Week High
  • AGIO $62.58
  • AFYA $19.90
  • Technical
  • Relative Strength Index (RSI)
  • AGIO 65.51
  • AFYA 43.10
  • Support Level
  • AGIO $29.05
  • AFYA $18.35
  • Resistance Level
  • AGIO $30.45
  • AFYA $19.23
  • Average True Range (ATR)
  • AGIO 1.13
  • AFYA 0.66
  • MACD
  • AGIO 0.33
  • AFYA -0.16
  • Stochastic Oscillator
  • AGIO 91.98
  • AFYA 13.37

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.

About AFYA Afya Limited

Afya Ltd is a medical education group based in Brazil. Its education portfolio has several courses in addition to Medicine, such as Management, Dentistry, Law, Engineering, Nursing, Psychology, and Accounting Sciences, among others. It has three segments; Undergrad provides educational services through undergraduate courses related to medicine, other health sciences, and other undergraduate programs, Continuing Education provides specialization programs and graduate courses in medicine; and Digital Services provides content and technology for medical education, clinical decisions software, practice management tools (that encompass electronic medical records, telemedicine, and digital prescription, and provides access, demand and efficiency for the healthcare players.

Share on Social Networks: